Tredje AP fonden Has $14.70 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Tredje AP fonden increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 662.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 223,664 shares of the biotechnology company's stock after acquiring an additional 194,334 shares during the period. Tredje AP fonden owned 0.12% of BioMarin Pharmaceutical worth $14,701,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in BMRN. TD Private Client Wealth LLC increased its stake in shares of BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 186 shares during the period. SBI Securities Co. Ltd. acquired a new stake in BioMarin Pharmaceutical in the 4th quarter valued at approximately $36,000. Meeder Asset Management Inc. increased its position in BioMarin Pharmaceutical by 920.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company's stock worth $52,000 after buying an additional 663 shares during the period. True Wealth Design LLC lifted its holdings in shares of BioMarin Pharmaceutical by 13,400.0% during the third quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company's stock worth $57,000 after buying an additional 804 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in shares of BioMarin Pharmaceutical by 111.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 885 shares of the biotechnology company's stock valued at $58,000 after acquiring an additional 466 shares during the period. 98.71% of the stock is owned by institutional investors.

Remove Ads

BioMarin Pharmaceutical Price Performance

Shares of BMRN traded down $0.03 on Tuesday, hitting $71.52. The company's stock had a trading volume of 1,167,710 shares, compared to its average volume of 1,771,381. The company has a market capitalization of $13.64 billion, a PE ratio of 32.51, a PEG ratio of 0.61 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a fifty-two week low of $60.63 and a fifty-two week high of $94.85. The company has a 50 day moving average price of $66.31 and a 200 day moving average price of $68.51. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. The company had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. On average, research analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Erin Burkhart sold 1,344 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the transaction, the chief accounting officer now directly owns 13,105 shares in the company, valued at approximately $896,119.90. This represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.85% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on BMRN shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $90.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. UBS Group upped their price objective on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Oppenheimer raised BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price on the stock in a research report on Monday, February 24th. Scotiabank upped their price target on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a report on Thursday, February 20th. Finally, Wedbush reiterated an "outperform" rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $94.00.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.